Background and Purpose-Dysglycemia may influence the predictive value of CYP2C19 loss-of-function allele for clinical efficacy of antiplatelet drug, but the role of glycated albumin (GA) remains unclear in patients with stroke on antiplatelet drugs. Methods-The CHANCE trial (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events) included 2933 patients who had GA levels and CYP2C19 genotyping. Cox proportional hazards model was used to assess the interaction between CYP2C19 loss-of-function allele (*2, *3) carrier status and the effect of antiplatelet therapy based on their GA levels. Results-There was significant interaction between carrier status and antiplatelet therapy regimen on the risk of recurrent stroke (P=0.03) in patients with GA levels of ≤15.5%, but not in those with GA levels of >15.5% (P=0.48). Only in noncarriers with low GA levels, dual-antiplatelet therapy reduced stroke recurrence (3.5%) compared with those on aspirin alone (14.7%; hazard ratio, 0.23; 95% confidence interval, 0.10-0.49; P<0.001). Similar effects were observed when examined the combined vascular event or ischemic stroke. No significant difference in bleeding was found among groups. 
C lopidogrel combined with aspirin has been recommended for secondary stroke prevention in patients with acute minor stroke or high-risk transient ischemic attack (TIA). 1, 2 In the genetic substudy of the CHANCE trial (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events), 3 the benefit of reduced stroke recurrence only was seen in patients on clopidogrel-aspirin but without CYP2C19 loss-of-function allele (*2 and *3). 4 Genetic variant of CYP2C19 is one of the most prominent genetic discoveries to explain poor response to clopidogrel [5] [6] [7] [8] and accountable for ≈20% of such response variability. 9, 10 Some noncarriers with minor stroke or TIA still develop new ischemic events in spite of dual-antiplatelet therapy. The predictive value of genetic variants of CYP2C19 for high antiplatelet reactivity and cardiovascular events is reportedly decreased by diabetes mellitus (DM) in patients with coronary artery disease receiving dual-antiplatelet therapy. 11, 12 Our previous findings demonstrated that among patients with minor stroke or TIA, poor short-term (2-4 weeks) glycemic control, defined as glycated albumin (GA) levels of >15.5%, was associated with impaired clinical efficacy of clopidogrel unrelated to diabetic status during a 90-day follow-up. 13 The present study aimed at assessing the impact of GA on the interaction between CYP2C19 lossof-function allele carrier status and effect of dual-antiplatelet therapy in patients with minor stroke or TIA enrolled in the CHANCE trial.
Methods

Study Population
The detailed design, methods, and main findings of the CHANCE trial have been previously reported. 3, 14 The CHANCE trial was a randomized, double-blind, placebo-controlled clinical trial conducted in China and approved by the ethics committee of each participating center. It was registered with the US National Institutes of Health clinical trial registry, number NCT00979589. Written informed consent was obtained from all participants or their legal proxies. Briefly, the CHANCE trial compared the efficacy of dual-antiplatelet therapy with aspirin alone for secondary stroke prevention in patients with acute minor stroke (National Institute Health Stroke Scale score 0-3) or moderate-to high-risk TIA (ABCD2 score ≥ 4). Patients on dualantiplatelet therapy received clopidogrel at a loading dose of 300 mg followed by a maintenance dose of 75 mg daily for 3 months, plus aspirin at a loading dose of 75 to 300 mg followed by 75 mg daily for 21 days. Patients in the group received aspirin at a loading dose of 75 to 300 mg followed by 75 mg daily for 3 months. Of 114 centers in the CHANCE trial, 73 voluntarily participated in the prespecified substudy.
Data Collection
Baseline data collected include demographics (age and sex), body mass index, cigarette smoking status, and previous history of ischemic stroke, TIA, DM, hypertension, hypercholesterolemia, myocardial infarction, angina, congestive heart failure, known atrial fibrillation or flutter, and valvular heart disease. The concomitant use of lipid-lowering, hypoglycemic or antihypertensive agents, and proton pump inhibitors during hospitalization was recorded.
Clinical Outcomes
The primary efficacy outcome was a new ischemic or hemorrhagic stroke in 90 days. The secondary efficacy outcome was the combined vascular events (ischemic stroke, hemorrhagic stroke, myocardial infarction, or vascular death). The safety outcome was any bleeding according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries criteria.
CYP2C19 Genotype and GA Level Assessment
Blood samples were collected and shipped through cold-chain from each site to Tiantan Hospital, Beijing, China, and stored at −80°C. Three CYP2C19 single-nucleotide polymorphisms (SNPs) were assessed, including CYP2C19*2 (681G>A, dbSNP rs4244285), CYP2C19*3 (636G>A, dbSNP rs4986893), and CYP2C19*17 (−806C>T, dbSNP rs12248560). Genotyping of the 3 SNPs was performed on the Sequenom MassARRAY iPLEX platform, as described previously. 4 The call rate was >98.5% for each SNP. Loss-of-function allele carrier was defined as an individual with at least 1 CYP2C19 loss-of-function allele (*2 or *3), including *1/*2, *1/*3, *2/*17, *3/*17, *2/*2, *2/*3, and *3/*3. Serum GA levels were assessed with a specific kit (catalog number 4085-717; Ruiyuan Bio-Technique Co. Ltd., Ningbo, China) on a Roche Modular P800 system in the clinical laboratory of Tiantan Hospital. 13 The GA level was expressed as a percentage of total serum albumin. The interassay coefficient of variation was 2%. GA levels of >15.5% were defined as high and poor glycemic control, whereas those of ≤15.5% were considered to be low and good glycemic control. 13 All measurements were performed by the laboratory personnel blinded to study group assignments and clinical outcomes.
Statistical Analysis
The participants included in the current analysis were classified into 2 subgroups according to a GA cutoff value of 15.5%. 13 Baseline characteristics were compared between the carriers and noncarriers stratified by GA levels. Medians with interquartile ranges were used for continuous variables with skewed distribution. Proportions were used for categorical variables. Continuous variables were compared by the nonparametric Wilcoxon or Kruskal-Wallis test. Categorical variables were tested by χ 2 test or Fisher exact test. Kaplan-Meier analyses were used to generate survival plots of time to stroke recurrence during the 90-day follow-up period, and groups were compared by the log-rank test. Differences between groups on dual or mono antiplatelet treatment in terms of the rate of stroke (ischemic or hemorrhagic), combined vascular events, ischemic stroke, or any bleeding during the 90-day follow-up were assessed by Cox proportional hazards regression model. Multivariable Cox regression analyses were adjusted by age, sex, body mass index, previous or current smoking status, time to randomization, minor stroke or TIA at randomization, and medical history of any ischemic stroke, TIA, hypertension, DM, and hyperlipidemia, with pooled study centers (≥20 patients) as a random effect. The interaction of CYP2C19 loss-of-function allele carrier status with treatment was analyzed by the above crude and multivariable Cox models. Two-sided P<0.05 was considered statistically significant. All statistical analyses were conducted with SAS software, version 9.4 (SAS Institute, Inc., Cary, NC).
Results
Patient Characteristic
A total of 2933 patients with GA levels were successfully genotyped for all 3 SNPs. 4 Compared with patients enrolled in CHANCE but excluded from this study, the subjects in this analysis had less history of ischemic stroke, DM, and hypercholesterolemia, but more with mild symptoms and on antihypertension agents. 4 Among them, 1089 patients (37.1%) showed low GA levels and 1844 (62.9%) had high GA levels. CYP2C19 loss-of-function allele carriers represented 57.8% (629/1089 patients) in patients with low GA level, and 59.5% (1097/1844 patients) in patients with high GA levels (P=0.37). Regardless of their serum GA levels, carriers and noncarriers were well balanced on their baseline characteristics (Table) .
Interaction of Carrier Status With Antiplatelet Therapy Stratified by GA Levels
As shown in Figure 1 , there were significant interactions between the CYP2C19 loss-of-function allele carrier status and antiplatelet therapy regimen on the risks of recurrent stroke (P=0.03), combined vascular events (P=0.03), and ischemic stroke (P=0.01) for patients with low GA levels, but not in those with elevated GA (P=0.48, P=0.52, and P=0.51, respectively) levels. Among noncarriers with low GA levels, clopidogrel plus aspirin reduced the risk of recurrent stroke (3.5%) compared with those on aspirin alone (14.7%, unadjusted hazard ratio, 0.23; 95% confidence interval, 0.10-0.49; P<0.001). However, the risk of new stroke was not significantly reduced by clopidogrel plus aspirin in carriers with low GA levels (unadjusted hazard ratio, 0.62; 95% confidence interval, 0.34-1.11; P=0.11). Similar results were observed for the outcome of combined vascular events and ischemic stroke. Only in noncarriers with low GA levels, clopidogrel plus aspirin markedly reduced the rate of combined vascular events (hazard ratio, 0.22; 95% confidence interval,
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April 2017 0.10-0.48; P<0.001) and ischemic stroke (hazard ratio, 0.17; 95% confidence interval, 0.07-0.41; P<0.001) compared with those on aspirin alone. The effects of dual-and monoantiplatelet therapies in preventing recurrent clinical events were not significantly different among patients with elevated GA levels, regardless of their carrier status. After adjustment for age, sex, body mass index, and history of DM, the interactions of carrier status with antiplatelet therapy on the risk of recurrent stroke (P=0.02), combined vascular event (P=0.02), and ischemic stroke (P=0.01) persisted even in patients without elevated GA levels ( Table I in Clopidogrel plus aspirin did not increase the rate of hemorrhage in all subgroups. There was no interaction between carrier status and antiplatelet therapy on hemorrhagic events in patients with either low (P=0.64) or high (P=0.27) GA levels. (Figure 1 ; Figure II in the online-only Data Supplement).
Discussion
In this study, the associations between CYP2C19 loss-of-function allele carrier status and clopidogrel efficacy were significant only in patients with GA levels of ≤15.5%, and not in those with high GA levels. Among noncarriers with low GA levels who had minor stroke or TIA, clopidogrel plus aspirin reduced the risk of recurrent stroke by 77% compared with those on aspirin alone, without increased risk of hemorrhage. The risk of recurrence was increased by >3-fold in noncarriers with low GA levels on aspirin alone, compared with patients with clopidogrel-aspirin treatment. Furthermore, in patients treated with clopidogrel plus aspirin, the absolute risk difference of stroke recurrence was 4.7% between the original CHANCE population 3 and those included in the current study (8.2% versus 3.5%).
A recent systematic review and meta-analysis demonstrated that CYP2C19 loss-of-function alleles were the most important genetic variants associated with clinical outcomes in patients on clopidogrel for ischemic stroke or TIA. 8 Despite BMI indicates body mass index (calculated as weight in kilograms divided by height in meters squared); GA, glycated albumin; and IQR, interquartile range. *Carriers were defined as patients with at least 1 CYP2C19 loss-of-function allele (*2 or *3): *1/*2, *1/*3, *2/*2, *2/*3, *3/*3,*2/*17, or *3/*17. †Noncarriers were defined as patients without any CYP2C19 loss-of-function allele: *1/*1, *1/*17, or *17/*17.
dual-antiplatelet therapy, 6.7% of noncarriers experienced a new stroke within 90 days in the CHANCE trial. 4 Indeed, not all noncarriers with minor stroke or TIA could benefit from dual-antiplatelet therapy. Nongenetic factors might affect the association of CYP2C19 polymorphisms with the variability of responses to clopidogrel.
Dysglycemia might be one of the most relevant variables of many clinical events. 9 In 333 patients with myocardial infarction from the ELEVATE-TIMI 56 study (Escalating Clopidogrel by Involving a Genetic Strategy-Thrombolysis in Myocardial Infarction 56), the 4-fold clopidogrel maintenance dose in diabetic carriers achieved a similar on-treatment platelet reactivity compared with the standard dose in noncarriers without DM. 11 A prospective single-center study showed that the impact of CYP2C19 loss-of-function allele carriage on the clinical outcome might be more apparent in non-DM than in DM, assessing 519 Japanese patients with coronary stents. 12 Even though DM is associated with high platelet reactivity, [15] [16] [17] [18] the effects of DM on the clinical efficacy of clopidogrel remain controversial. Impaired clinical efficacy of clopidogrel in DM was demonstrated in a Danish cohort of nearly 60 000 patients with myocardial infarction. [19] [20] [21] [22] Growing evidence suggests that the glycemic control rather than the diabetic status predict the effects of dual-or monoantiplatelet therapy. [23] [24] [25] [26] [27] Hemoglobin A1c is a widely used marker reflecting the long-term (2-3 months) effect of glycemic control. 28 GA represents a short-term (2-4 weeks) exposure to glucose, because of a shorter half-life of albumin compared with hemoglobin. 29 Compared with hemoglobin A1c, GA can more accurately reflect the actual status of glycemic control and rapid response to changes in treatment. 30 Also, GA can be a better marker for patients with anemia, hemoglobinpathies, or undergoing dialysis. 28 The predictive value of GA has been assessed previously in a substudy of the CHANCE trial. 13 Clopidogrel plus aspirin was superior to aspirin alone in patients with GA levels of ≤15.5% for the risk of stroke, and the superiority of clopidogrel was not significant in patients with GA levels of >15.5%. 13 However, no study has evaluated the interaction of CYP2C19 loss-of-function carrier status with antiplatelet therapy stratified by GA levels in patients with minor stroke or TIA.
In this analysis, the protective effect of dual-antiplatelet therapy was apparent in patients with neither CYP2C19 lossof-function allele nor elevated GA levels. There were significant differences in the risk of recurrent stroke, combined vascular events, and ischemic stroke, between carriers and noncarriers for patients with GA levels of ≤15.5%. However, no difference was found in patients with elevated GA levels. These findings suggested that the interactions between CYP2C19 genetic variants and efficacy of clopidogrel were offset by poor glycemic control. Because GA correlates with history of DM, its impact on the interactions of genetic variants with antiplatelet therapy might be related to DM. However, in our analysis, similar findings were still present even after adjustment for the history of DM and other factors in multivariate Cox models, which suggested that the effects of GA were independent of previous diagnoses of DM. Combination of GA and carrier status could predict the effects of clopidogrel plus aspirin in patients with minor stroke or TIA more accurately. Glycemic control was key in secondary stroke prevention in all patients on clopidogrelaspirin therapy, even in those without CYP2C19 loss-offunction allele.
The mechanism underlying these effects remains unclear. Elevated GA levels reflect poor glycemic control for at least 2 to 4 weeks before stroke. Hyperglycemia decreases the active metabolite of clopidogrel, 17, 31 which could increase the platelet reactivity by upregulating platelet P-selectin 32 and protein kinase C, 33 via the glycation of platelet surface proteins and osmotic effects of glucose. 34 Exposure to hyperglycemia would also induce epigenetic changes. CYP2C19 is related to the function of the methylation sites, as evidenced by the presence of CpG islands. 35 Hyperglycemia-induced abnormal DNA methylation or demethylation would influence the subsequent gene transcription and expression. 
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Our study has several limitations. First, it was a post hoc analysis with limited statistic power. In addition, the history of DM was self-reported before admission. Some patients could be misdiagnosed. Furthermore, status of insulin resistance was not assessed, which could lead to the abnormal platelet P2Y12 receptor signaling in diabetic patients. Moreover, GA levels were assessed only at baseline. A dynamic evaluation of GA levels could be informative. Finally, all participants were Chinese. The prevalence of CYP2C19 loss-of-function allele in Chinese is much more higher than that in white, and GA levels may vary among races and ethnicities. 37 Therefore, current findings should be interpreted with caution. Further studies are required to confirm our findings, especially in nonAsian populations.
Conclusions
In Chinese patients with minor stroke or TIA, noncarrier status of CYP2C19 loss-of-function allele and normal GA levels Figure 2 . Cumulative probability of stroke according to CYP2C19 loss-of-function allele carrier status and glycated albumin (GA) levels (A) ≤15.5% and (B) >15.5%. Carriers were defined as patients with at least one CYP2C19 loss-of-function allele (*2 or *3): *1/*2, *1/*3, *2/*2, *2/*3, *3/*3,*2/*17, or *3/*17. Noncarriers were defined as patients without any CYP2C19 loss-of-function allele: *1/*1, *1/*17, or *17/*17. Stroke was defined as a new stroke including both ischemic and hemorrhagic stroke.
were associated with a greater benefit of clopidogrel plus aspirin therapy in reducing new stroke compared with aspirin alone. Poor glycemic control attenuated the interactions of CYP2C19 genetic variants with dual-antiplatelet therapy on clinical outcomes.
